Compare Stocks: REPL, RCUS, LEGN, and GMTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMTX Gemini Therapeutics	$77.00 -2.8%	$72.51	$1.16 ▼ $14.10	$3.34B	-0.12	189,291 shs	364,286 shs
LEGN Legend Biotech	$19.01 +2.5%	$27.98	$16.24 ▼ $39.16	$3.53B	0.34	2.50 million shs	610,914 shs
RCUS Arcus Biosciences	$27.65 -1.9%	$27.00	$8.88 ▼ $31.74	$3.47B	0.8	1.24 million shs	236,407 shs
REPL Replimune Group	$11.30 +0.8%	$9.49	$1.50 ▼ $12.50	$951.59M	0.86	4.91 million shs	3.23 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMTX Gemini Therapeutics	0.00%	+3.89%	+0.97%	+15.08%	+30.57%
LEGN Legend Biotech	0.00%	-16.52%	-37.98%	-21.36%	-52.19%
RCUS Arcus Biosciences	0.00%	-0.82%	-7.37%	+9.54%	+207.61%
REPL Replimune Group	0.00%	+15.46%	-3.28%	+348.00%	+47.37%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMTX Gemini Therapeutics	$77.00 -2.8%	$72.51	$1.16 ▼ $14.10	$3.34B	-0.12	189,291 shs	364,286 shs
LEGN Legend Biotech	$19.01 +2.5%	$27.98	$16.24 ▼ $39.16	$3.53B	0.34	2.50 million shs	610,914 shs
RCUS Arcus Biosciences	$27.65 -1.9%	$27.00	$8.88 ▼ $31.74	$3.47B	0.8	1.24 million shs	236,407 shs
REPL Replimune Group	$11.30 +0.8%	$9.49	$1.50 ▼ $12.50	$951.59M	0.86	4.91 million shs	3.23 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMTX Gemini Therapeutics	0.00%	+3.89%	+0.97%	+15.08%	+30.57%
LEGN Legend Biotech	0.00%	-16.52%	-37.98%	-21.36%	-52.19%
RCUS Arcus Biosciences	0.00%	-0.82%	-7.37%	+9.54%	+207.61%
REPL Replimune Group	0.00%	+15.46%	-3.28%	+348.00%	+47.37%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
LEGN Legend Biotech	2.53	Moderate Buy	$55.29	190.76% Upside
RCUS Arcus Biosciences	2.58	Moderate Buy	$36.40	31.63% Upside
REPL Replimune Group	2.33	Hold	$9.29	-17.79% Downside

Current Analyst Ratings Breakdown

Latest REPL, RCUS, LEGN, and GMTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2026	REPL Replimune Group	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$9.00 ➝ $12.00
7/31/2026	REPL Replimune Group	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/30/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/28/2026	LEGN Legend Biotech	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/28/2026	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
7/27/2026	LEGN Legend Biotech	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$49.00 ➝ $28.00
7/27/2026	LEGN Legend Biotech	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$58.00
7/27/2026	LEGN Legend Biotech	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$63.00 ➝ $59.00
7/24/2026	LEGN Legend Biotech	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$49.00 ➝ $28.00
7/20/2026	REPL Replimune Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/20/2026	RCUS Arcus Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $45.00

(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
LEGN Legend Biotech	$1.14B	3.10	N/A	N/A	$5.43 per share	3.50
RCUS Arcus Biosciences	$236M	14.74	N/A	N/A	$5.84 per share	4.74
REPL Replimune Group	N/A	N/A	N/A	N/A	$2.01 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
LEGN Legend Biotech	-$296.80M	-$0.68	N/A	12.19	N/A	-21.98%	-24.92%	-14.87%	8/11/2026 (Estimated)
RCUS Arcus Biosciences	-$353M	-$3.18	N/A	N/A	N/A	-156.36%	-68.97%	-35.27%	8/5/2026 (Estimated)
REPL Replimune Group	-$313.94M	-$3.38	N/A	N/A	N/A	N/A	-128.57%	-82.35%	8/6/2026 (Estimated)

Latest REPL, RCUS, LEGN, and GMTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	LEGN Legend Biotech	$0.0563	N/A	N/A	N/A	$355.96 million	N/A
8/6/2026	Q1 2027	REPL Replimune Group	-$0.6437	N/A	N/A	N/A	$13.60 million	N/A
8/5/2026	Q2 2026	RCUS Arcus Biosciences	-$0.8912	N/A	N/A	N/A	$22.22 million	N/A
6/29/2026	Q4 2026	REPL Replimune Group	-$0.6613	-$0.76	-$0.0988	-$0.76	$3.57 million	N/A
5/13/2026	Q1 2026	LEGN Legend Biotech	-$0.02	-$0.03	-$0.01	-$0.30	$306.51 million	$305.10 million
5/5/2026	Q1 2026	RCUS Arcus Biosciences	-$0.92	-$1.02	-$0.10	-$1.02	$29.49 million	$17.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GMTX Gemini Therapeutics	N/A	71.49	71.49
LEGN Legend Biotech	N/A	2.13	2.05
RCUS Arcus Biosciences	0.19	4.04	4.04
REPL Replimune Group	0.63	4.79	4.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GMTX Gemini Therapeutics	75.42%
LEGN Legend Biotech	70.89%
RCUS Arcus Biosciences	92.89%
REPL Replimune Group	92.53%

Insider Ownership

Company	Insider Ownership
GMTX Gemini Therapeutics	12.90%
LEGN Legend Biotech	0.02%
RCUS Arcus Biosciences	7.60%
REPL Replimune Group	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
LEGN Legend Biotech	2,965	185.74 million	185.70 million	Optionable
RCUS Arcus Biosciences	500	125.77 million	116.21 million	Optionable
REPL Replimune Group	210	84.03 million	79.49 million	Optionable

REPL, RCUS, LEGN, and GMTX Headlines

Recent News About These Companies

Why Replimune Group (REPL) Is Up 15.5% After Key FDA Panel Backing For RP1 Data - And What's Next

2 hours ago | finance.yahoo.com

Replimune Group (NASDAQ:REPL) Upgraded at Piper Sandler

August 3 at 1:48 AM | americanbankingnews.com

120,400 Shares in Replimune Group, Inc. $REPL Purchased by Seven Fleet Capital Management LP

August 2 at 6:31 AM | marketbeat.com

Analysts Set Replimune Group, Inc. (NASDAQ:REPL) Price Target at $8.86

August 2 at 4:17 AM | americanbankingnews.com

Replimune Group (NASDAQ:REPL) Hits New 52-Week High Following Analyst Upgrade

August 2 at 3:14 AM | americanbankingnews.com

Replimune announces favourable outcome from US FDA’s Advisory Committee meeting for RP1 in advanced melanoma

August 1 at 9:14 AM | pharmabiz.comP

Replimune Group (NASDAQ:REPL) Rating Increased to Strong-Buy at Piper Sandler

August 1 at 8:05 AM | marketbeat.com

FDA panel backs Replimune melanoma drug RP1 in 10-3 vote

July 31 at 5:19 PM | yahoo.com

Securities Fraud Investigation Into Replimune Group Inc. (REPL) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

July 31 at 11:00 AM | globenewswire.com

Replimune Group (NASDAQ:REPL) Sets New 52-Week High - Here's What Happened

July 31 at 10:59 AM | marketbeat.com

REPL Stock Tracks Best Day Ever: This Analyst Sees Higher Approval Odds For Replimune’s Melanoma After ‘Overwhelmingly Positive’ Panel Outcome

July 31 at 7:18 AM | finance.yahoo.com

Replimune surges after FDA advisers back skin cancer drug

July 31 at 5:40 AM | reuters.com

Why Is REPL Stock Soaring 127% After Hours Today?

July 31 at 1:35 AM | finance.yahoo.com

FDA expert committee votes in favor of Replimune’s melanoma treatment

July 30, 2026 | statnews.comS

Replimune melanoma drug wins support of FDA panel

July 30, 2026 | yahoo.com

US FDA advisers back Replimune skin cancer drug trial data

July 30, 2026 | msn.com

FDA panel votes in favor of Replimune’s melanoma treatment

July 30, 2026 | msn.com

Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma

July 30, 2026 | globenewswire.com

US FDA panel backs Replimune skin cancer drug study data

July 30, 2026 | reuters.com

Bragar Eagel & Squire, P.C. is Investigating Replimune Group Inc. on Behalf of Replimune Stockholders and Encourages Investors to Contact the Firm

July 30, 2026 | globenewswire.com

A Food and Drug Administration advisory panel voted 10-3 for Replimune Group's experimental melanoma therapy, after experts raised doubts about whether the company's data and trial design could be trusted to show the drug works

July 30, 2026 | wsj.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

REPL, RCUS, LEGN, and GMTX Company Descriptions

Gemini Therapeutics NASDAQ:GMTX

$77.00 -2.21 (-2.79%)

As of 07/31/2026

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Legend Biotech NASDAQ:LEGN

$19.01 +0.46 (+2.50%)

As of 12:28 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Arcus Biosciences NYSE:RCUS

$27.65 -0.54 (-1.90%)

As of 12:28 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Replimune Group NASDAQ:REPL

$11.30 +0.10 (+0.85%)

As of 12:28 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest REPL, RCUS, LEGN, and GMTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest REPL, RCUS, LEGN, and GMTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

REPL, RCUS, LEGN, and GMTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

REPL, RCUS, LEGN, and GMTX Company Descriptions

Gemini Therapeutics NASDAQ:GMTX

Legend Biotech NASDAQ:LEGN

Arcus Biosciences NYSE:RCUS

Replimune Group NASDAQ:REPL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest REPL, RCUS, LEGN, and GMTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest REPL, RCUS, LEGN, and GMTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

REPL, RCUS, LEGN, and GMTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

REPL, RCUS, LEGN, and GMTX Company Descriptions

Gemini Therapeutics NASDAQ:GMTX

Legend Biotech NASDAQ:LEGN

Arcus Biosciences NYSE:RCUS

Replimune Group NASDAQ:REPL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools